Enterolactone and breast cancer: methodological issues may contribute to conflicting results in observational studies

Nutrition Research

Volumn 30, Issue 10, 2010, Pages 667-677

  Sonestedt, Emily ^a   Wirfält, Elisabet ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Breast neoplasms; Diet; Enterolactone; Epidemiology; Lignans

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; ENTEROLACTONE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LIGNIN; PROGESTERONE RECEPTOR;

AGE DISTRIBUTION; ANALYTIC METHOD; ANALYTICAL ERROR; BLOOD LEVEL; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CHEMICAL STRUCTURE; CORRELATION COEFFICIENT; DIETARY INTAKE; DNA POLYMORPHISM; FACTORIAL ANALYSIS; FIBER; FOOD COMPOSITION; FOOD QUALITY; GENETIC RISK; HETEROZYGOTE; HUMAN; INTESTINE FLORA; LIFESTYLE; METHODOLOGY; NONHUMAN; OBESITY; OBSERVATIONAL STUDY; PHOTOCHEMISTRY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RELIABILITY; REVIEW; RISK FACTOR; RISK REDUCTION; TISSUE SECTION;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LIGNANS; PHYTOESTROGENS; PHYTOTHERAPY;

EID: 78149274896     PISSN: 02715317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nutres.2010.09.010     Document Type: Review

References (103)

1. Key T., Appleby P., Barnes I., Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002, 94:606-616.
2. Zeleniuch-Jacquotte A., Shore R.E., Koenig K.L., Akhmedkhanov A., Afanasyeva Y., Kato I., et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 2004, 90:153-159.
3. Onland-Moret N.C., Kaaks R., van Noord P.A., Rinaldi S., Key T., Grobbee D.E., et al. Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. Br J Cancer 2003, 88:1394-1399.
4. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997, 350:1047-1059. Collaborative Group on Hormonal Factors in Breast Cancer.
5. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
6. Adlercreutz H. Lignans and human health. Crit Rev Clin Lab Sci 2007, 44:483-525.
7. Keinan-Boker L., Peeters P.H., Mulligan A.A., Navarro C., Slimani N., Mattisson I., et al. Soy product consumption in 10 European countries: the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr 2002, 5:1217-1226.
8. Mazur W. Phytoestrogen content in foods. Bailliere's Clin Endocrinol Metab 1998, 12:729-742.
9. Mazur W., Fotsis T., Wahala K., Ojala S., Salakka A., Adlercreutz H. Isotope dilution gas chromatographic-mass spectrometric method for the determination of isoflavonoids, coumestrol, and lignans in food samples. Anal Biochem 1996, 233:169-180.
10. Mazur W.M., Uehara M., Wahala K., Adlercreutz H. Phyto-oestrogen content of berries, and plasma concentrations and urinary excretion of enterolactone after a single strawberry-meal in human subjects. Br J Nutr 2000, 83:381-387.
11. Mazur W.M., Wahala K., Rasku S., Salakka A., Hase T., Adlercreutz H. Lignan and isoflavonoid concentrations in tea and coffee. Br J Nutr 1998, 79:37-45.
12. Heinonen S., Nurmi T., Liukkonen K., Poutanen K., Wahala K., Deyama T., et al. In vitro metabolism of plant lignans: new precursors of mammalian lignans enterolactone and enterodiol. J Agric Food Chem 2001, 49:3178-3186.
13. Lampe J.W. Isoflavonoid and lignan phytoestrogens as dietary biomarkers. J Nutr 2003, 133(Suppl 3):956S-964S.
14. Patisaul HB, Jefferson W. The pros and cons of phytoestrogens. Front Neuroendocrinol [Epub ahead of print].
15. Kwon M., Davin L.B., Lewis N.G. In situ hybridization and immunolocalization of lignan reductases in woody tissues: implications for heartwood formation and other forms of vascular tissue preservation. Phytochemistry 2001, 57:899-914.
16. Setchell K.D.R., Adlercreutz H. The excretion of two new phenolic compounds (180/442 and 180/410) during the human menstrual cycle and in pregnancy. J Steroid Biochem 1979, 11:xv-xvi.
17. Adlercreutz H., Fotsis T., Heikkinen R., Dwyer J.T., Goldin B.R., Gorbach S.L., et al. Diet and urinary excretion of lignans in female subjects. Medical biology 1981, 59:259-261.
18. Adlercreutz H., Fotsis T., Heikkinen R., Dwyer J.T., Woods M., Goldin B.R., et al. Excretion of the lignans enterolactone and enterodiol and of equol in omnivorous and vegetarian postmenopausal women and in women with breast cancer. Lancet 1982, 2:1295-1299.
19. Axelson M., Sjovall J., Gustafsson B.E., Setchell K.D. Origin of lignans in mammals and identification of a precursor from plants. Nature 1982, 298:659-660.
20. Borriello S.P., Setchell K.D., Axelson M., Lawson A.M. Production and metabolism of lignans by the human faecal flora. J Appl Bacteriol 1985, 58:37-43.
21. Penalvo J.L., Heinonen S.M., Aura A.M., Adlercreutz H. Dietary sesamin is converted to enterolactone in humans. J Nutr 2005, 135:1056-1062.
22. Liu Z., Saarinen N.M., Thompson L.U. Sesamin is one of the major precursors of mammalian lignans in sesame seed (Sesamum indicum) as observed in vitro and in rats. J Nutr 2006, 136:906-912.
23. Begum A.N., Nicolle C., Mila I., Lapierre C., Nagano K., Fukushima K., et al. Dietary lignins are precursors of mammalian lignans in rats. J Nutr 2004, 134:120-127.
24. Saarinen N.M., Warri A., Makela S.I., Eckerman C., Reunanen M., Ahotupa M., et al. Hydroxymatairesinol, a novel enterolactone precursor with antitumor properties from coniferous tree (Picea abies). Nutr Cancer 2000, 36:207-216.
25. Eeckhaut E., Struijs K., Possemiers S., Vincken J.P., Keukeleire D.D., Verstraete W. Metabolism of the lignan macromolecule into enterolignans in the gastrointestinal lumen as determined in the simulator of the human intestinal microbial ecosystem. J Agric Food Chem 2008, 56:4806-4812.
26. Smeds A.I., Saarinen N.M., Hurmerinta T.T., Penttinen P.E., Sjoholm R.E., Makela S.I. Urinary excretion of lignans after administration of isolated plant lignans to rats: the effect of single dose and ten-day exposures. J Chromatogr 2004, 813:303-312.
27. Rowland I.R., Wiseman H., Sanders T.A., Adlercreutz H., Bowey E.A. Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. Nutr Cancer 2000, 36:27-32.
28. Tarpila S., Aro A., Salminen I., Tarpila A., Kleemola P., Akkila J., et al. The effect of flaxseed supplementation in processed foods on serum fatty acids and enterolactone. Eur J Clin Nutr 2002, 56:157-165.
29. Nesbitt P.D., Lam Y., Thompson L.U. Human metabolism of mammalian lignan precursors in raw and processed flaxseed. Am J Clin Nutr 1999, 69:549-555.
30. Rowland I., Faughnan M., Hoey L., Wahala K., Williamson G., Cassidy A. Bioavailability of phyto-oestrogens. Br J Nutr 2003, 89(Suppl 1):S45-S58.
31. Low Y.L., Dunning A.M., Dowsett M., Folkerd E., Doody D., Taylor J., et al. Phytoestrogen exposure is associated with circulating sex hormone levels in postmenopausal women and interact with ESR1 and NR1I2 gene variants. Cancer Epidemiol Biomarkers Prev 2007, 16:1009-1016.
32. Brooks J.D., Thompson L.U. Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol 2005, 94:461-467.
33. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998, 139:4252-4263.
34. Mueller S.O., Simon S., Chae K., Metzler M., Korach K.S. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci 2004, 80:14-25.
35. Penttinen P., Jaehrling J., Damdimopoulos A.E., Inzunza J., Lemmen J.G., van der Saag P., et al. Diet-derived polyphenol metabolite enterolactone is a tissue-specific estrogen receptor activator. Endocrinology 2007, 148:4875-4886.
36. Prasad K. Antioxidant activity of secoisolariciresinol diglucoside-derived metabolites, secoisolariciresinol, enterodiol, and enterolactone. Int J Angiol 2000, 9:220-225.
37. Bergman Jungestrom M., Thompson L.U., Dabrosin C. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clin Cancer Res 2007, 13:1061-1067.
38. Milder I.E., Arts I.C., van de Putte B., Venema D.P., Hollman P.C. Lignan contents of Dutch plant foods: a database including lariciresinol, pinoresinol, secoisolariciresinol and matairesinol. Br J Nutr 2005, 93:393-402.
39. Valsta L.M., Kilkkinen A., Mazur W., Nurmi T., Lampi A.M., Ovaskainen M.L., et al. Phyto-oestrogen database of foods and average intake in Finland. Br J Nutr 2003, 89(Suppl 1):S31-S38.
40. Ingram D., Sanders K., Kolybaba M., Lopez D. Case-control study of phyto-oestrogens and breast cancer. Lancet 1997, 350:990-994.
41. Pietinen P., Stumpf K., Mannisto S., Kataja V., Uusitupa M., Adlercreutz H. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland. Cancer Epidemiol Biomarkers Prev 2001, 10:339-344.
42. Dai Q., Franke A.A., Jin F., Shu X.O., Hebert J.R., Custer L.J., et al. Urinary excretion of phytoestrogens and risk of breast cancer among Chinese women in Shanghai. Cancer Epidemiol Biomarkers Prev 2002, 11:815-821.
43. Piller R., Chang-Claude J., Linseisen J. Plasma enterolactone and genistein and the risk of premenopausal breast cancer. Eur J Cancer Prev 2006, 15:225-232.
44. Olsen A., Knudsen K.E., Thomsen B.L., Loft S., Stripp C., Overvad K., et al. Plasma enterolactone and breast cancer incidence by estrogen receptor status. Cancer Epidemiol Biomarkers Prev 2004, 13:2084-2089.
45. Hulten K., Winkvist A., Lenner P., Johansson R., Adlercreutz H., Hallmans G. An incident case-referent study on plasma enterolactone and breast cancer risk. Eur J Nutr 2002, 41:168-176.
46. Kilkkinen A., Virtamo J., Vartiainen E., Sankila R., Virtanen M.J., Adlercreutz H., et al. Serum enterolactone concentration is not associated with breast cancer risk in a nested case-control study. Int J Cancer 2004, 108:277-280.
47. den Tonkelaar I., Keinan-Boker L., Veer P.V., Arts C.J., Adlercreutz H., Thijssen J.H., et al. Urinary phytoestrogens and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001, 10:223-228.
48. Verheus M., van Gils C.H., Keinan-Boker L., Grace P.B., Bingham S.A., Peeters P.H. Plasma phytoestrogens and subsequent breast cancer risk. J Clin Oncol 2007, 25:648-655.
49. Grace P.B., Taylor J.I., Low Y.L., Luben R.N., Mulligan A.A., Botting N.P., et al. Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European Prospective Investigation of Cancer and Nutrition-Norfolk. Cancer Epidemiol Biomarkers Prev 2004, 13:698-708.
50. Ward H.A., Chapelais G., Kuhnle G.G., Luben R., Khaw K.T., Bingham S. Breast cancer risk in relation to urinary and serum biomarkers of phytoestrogen exposure in the EPIC-Norfolk study. Breast Cancer Res 2008, 10:R32.
51. Sonestedt E., Borgquist S., Ericson U., Gullberg B., Olsson H., Adlercreutz H., et al. Enterolactone is differently associated with estrogen receptor {beta}-negative and -positive breast cancer in a Swedish nested case-control study. Cancer Epidemiol Biomarkers Prev 2008, 17:3241-3251.
52. World Cancer Research Fund American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective 2007, AICR, Washington DC.
53. Horner N.K., Kristal A.R., Prunty J., Skor H.E., Potter J.D., Lampe J.W. Dietary determinants of plasma enterolactone. Cancer Epidemiol Biomarkers Prev 2002, 11:121-126.
54. White E. Effects of biomarker measurement error on epidemiological studies. Application of biomarkers in cancer epidemiology 1997, 142:73-93. IARC Scientific Publications, Lyon, France. P. Toniolo (Ed.).
55. Rosner B., Spiegelman D., Willett W.C. Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. Am J Epidemiol 1992, 136:1400-1413.
56. Stumpf K. Serum enterolactone as biological marker and in breast cancer: from laboratory to epidemiological studies [dissertation]. Helsinki: University of Helsinki; 2004.
57. Vineis P. Sources of variation in biomarkers. Application of biomarkers in cancer epidemiology 1997, 59-71. IARC Scientific Publications, Lyon, France. P. Toniolo, P. Boffetta, D.E.G. Shuker, N. Rothman, B. Hulka, N. Pearce (Eds.).
58. Hankinson S.E., Manson J.E., Spiegelman D., Willett W.C., Longcope C., Speizer F.E. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev 1995, 4:649-654.
59. Stumpf K., Adlercreutz H. Short-term variations in enterolactone in serum, 24-hour urine, and spot urine and relationship with enterolactone concentrations. Clin Chem 2003, 49:178-181.
60. Zeleniuch-Jacquotte A., Adlercreutz H., Akhmedkhanov A., Toniolo P. Reliability of serum measurements of lignans and isoflavonoid phytoestrogens over a two-year period. Cancer Epidemiol Biomarkers Prev 1998, 7:885-889.
61. Sonestedt E., Ericson U., Gullberg B., Penalvo J.L., Adlercreutz H., Wirfalt E. Variation in fasting and non-fasting serum enterolactone concentrations in women of the Malmo Diet and Cancer cohort. Eur J Clin Nutr 2008, 62:1005-1009.
62. Hausner H., Johnsen N.F., Hallund J., Tetens I. A single measurement is inadequate to estimate enterolactone levels in danish postmenopausal women due to large intraindividual variation. J Nutr 2004, 134:1197-1200.
63. Li J.H., Awad A.B., Fink C.S., Wu Y.W., Trevisan M., Muti P. Measurement variability of plasma beta-sitosterol and campesterol, two new biomarkers for cancer prevention. Eur J Cancer Prev 2001, 10:245-249.
64. Simpson P.T., Reis-Filho J.S., Gale T., Lakhani S.R. Molecular evolution of breast cancer. J Pathol 2005, 205:248-254.
65. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996, 93:5925-5930.
66. Gruvberger-Saal S.K., Bendahl P.O., Saal L.H., Laakso M., Hegardt C., Eden P., et al. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 2007, 13:1987-1994.
67. Murphy L.C., Watson P.H. Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer?. Endocr Relat Cancer 2006, 13:327-334.
68. Borgquist S., Holm C., Stendahl M., Anagnostaki L., Landberg G., Jirstrom K. Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. J Clin Pathol 2008, 61:197-203.
69. Saji S., Hirose M., Toi M. Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemother Pharmacol 2005, 56(Suppl 1):21-26.
70. Duffy M.J. Estrogen receptors: role in breast cancer. Crit Rev Clin Lab Sci 2006, 43:325-347.
71. Matthews J., Gustafsson J.A. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 2003, 3:281-292.
72. Pelletier G., El-Alfy M. Immunocytochemical localization of estrogen receptors alpha and beta in the human reproductive organs. J Clin Endocrinol Metab 2000, 85:4835-4840.
73. Suzuki R., Rylander-Rudqvist T., Saji S., Bergkvist L., Adlercreutz H., Wolk A. Dietary lignans and postmenopausal breast cancer risk by oestrogen receptor status: a prospective cohort study of Swedish women. Br J Cancer 2008.
74. Touillaud M.S., Thiebaut A.C., Fournier A., Niravong M., Boutron-Ruault M.C., Clavel-Chapelon F. Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status. J Natl Cancer Inst 2007, 99:475-486.
75. Borgquist S., Jirstrom K., Anagnostaki L., Manjer J., Landberg G. Anthropometric factors in relation to different tumor biological subgroups of postmenopausal breast cancer. Int J Cancer 2008.
76. Lin C.Y., Strom A., Li Kong S., Kietz S., Thomsen J.S., Tee J.B., et al. Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res 2007, 9:R25.
77. Hankinson S.E., Hunter D. Breast cancer. Textbook of cancer epidemiology 2002, 599s. Oxford University Press, New York, NY. D. Hunter, D. Trichopoulos, H.-O. Adami (Eds.).
78. Piller R., Verla-Tebit E., Wang-Gohrke S., Linseisen J., Chang-Claude J. CYP17 genotype modifies the association between lignan supply and premenopausal breast cancer risk in humans. J Nutr 2006, 136:1596-1603.
79. Haiman C.A., Hankinson S.E., Spiegelman D., Colditz G.A., Willett W.C., Speizer F.E., et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 1999, 59:1015-1020.
80. Sonestedt E., Ivarsson M.I., Harlid S., Ericson U., Gullberg B., Carlson J., et al. The protective association of high plasma enterolactone with breast cancer is reasonably robust in women with polymorphisms in the estrogen receptor alpha and beta genes. J Nutr 2009, 139:993-1001.
81. Kilkkinen A., Stumpf K., Pietinen P., Valsta L.M., Tapanainen H., Adlercreutz H. Determinants of serum enterolactone concentration. Am J Clin Nutr 2001, 73:1094-1100.
82. Johnsen N.F., Hausner H., Olsen A., Tetens I., Christensen J., Knudsen K.E., et al. Intake of whole grains and vegetables determines the plasma enterolactone concentration of Danish women. J Nutr 2004, 134:2691-2697.
83. Milder I.E., Kuijsten A., Arts I.C., Feskens E.J., Kampman E., Hollman P.C., et al. Relation between plasma enterodiol and enterolactone and dietary intake of lignans in a Dutch endoscopy-based population. J Nutr 2007, 137:1266-1271.
84. Bowey E., Adlercreutz H., Rowland I. Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats. Food Chem Toxicol 2003, 41:631-636.
85. Kilkkinen A., Pietinen P., Klaukka T., Virtamo J., Korhonen P., Adlercreutz H. Use of oral antimicrobials decreases serum enterolactone concentration. Am J Epidemiol 2002, 155:472-477.
86. Kilkkinen A., Valsta L.M., Virtamo J., Stumpf K., Adlercreutz H., Pietinen P. Intake of lignans is associated with serum enterolactone concentration in Finnish men and women. J Nutr 2003, 133:1830-1833.
87. Horn-Ross P.L., Barnes S., Kirk M., Coward L., Parsonnet J., Hiatt R.A. Urinary phytoestrogen levels in young women from a multiethnic population. Cancer Epidemiol Biomarkers Prev 1997, 6:339-345.
88. Jacobs D.R., Tapsell L.C. Food, not nutrients, is the fundamental unit in nutrition. Nutr Rev 2007, 65:439-450.
89. Jacobs D.R., Steffen L.M. Nutrients, foods, and dietary patterns as exposures in research: a framework for food synergy. Am J Clin Nutr 2003, 78:508S-513S.
90. Sonestedt E. Plant foods, plasma enterolactone and breast cancer: with a focus on estrogen receptor status and genetic variation 2008, Department of Clinical Sciences Malmö, Lund University, Malmö.
91. Stumpf K., Pietinen P., Puska P., Adlercreutz H. Changes in serum enterolactone, genistein, and daidzein in a dietary intervention study in Finland. Cancer Epidemiol Biomarkers Prev 2000, 9:1369-1372.
92. Ley R.E., Turnbaugh P.J., Klein S., Gordon J.I. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
93. Fooks L.J., Gibson G.R. Probiotics as modulators of the gut flora. Br J Nutr 2002, 88(Suppl 1):S39-S49.
94. Van 't Veer P., van Leer E.M., Rietdijk A., Kok F.J., Schouten E.G., Hermus R.J., et al. Combination of dietary factors in relation to breast-cancer occurrence. Int J Cancer 1991, 47:649-653.
95. Wirfalt E., Mattisson I., Gullberg B., Olsson H., Berglund G. Fat from different foods show diverging relations with breast cancer risk in postmenopausal women. Nutr Cancer 2005, 53:135-143.
96. Kilkkinen A., Rissanen H., Klaukka T., Pukkala E., Heliovaara M., Huovinen P., et al. Antibiotic use predicts an increased risk of cancer. Int J Cancer 2008, 123:2152-2155.
97. Tamim H.M., Hanley J.A., Hajeer A.H., Boivin J.F., Collet J.P. Risk of breast cancer in relation to antibiotic use. Pharmacoepidemiol Drug Saf 2008, 17:144-150.
98. Kilkkinen A., Stumpf K., Pietinen P., Valsta L.M., Tapanainen H., Adlercreutz H. Determinants of serum enterolactone concentration. Am J Clin Nutr 2001, 73:1094-1100.
99. Johnsen N.F., Hausner H., Olsen A., Tetens I., Christensen J., Knudsen K.E., et al. Intake of whole grains and vegetables determines the plasma enterolactone concentration of Danish women. J Nutr 2004, 134:2691-2697.
100. Milder I.E., Kuijsten A., Arts I.C., Feskens E.J., Kampman E., Hollman P.C., Van 't Veer P. Relation between plasma enterodiol and enterolactone and dietary intake of lignans in a Dutch endoscopy-based population. J Nutr 2007, 137:1266-1271.
101. Lampe J.W., Gustafson D.R., Hutchins A.M., Martini M.C., Li S., Wahala K., et al. Urinary isoflavonoid and lignan excretion on a Western diet: relation to soy, vegetable, and fruit intake. Cancer Epidemiol Biomarkers Prev 1999, 8:699-707.
102. Vanharanta M., Voutilainen S., Nurmi T., Kaikkonen J., Roberts L.J., Morrow J.D., et al. Association between low serum enterolactone and increased plasma F2-isoprostanes, a measure of lipid peroxidation. Atherosclerosis 2002, 160:465-469.
103. Zeleniuch-Jacquotte A., Adlercreutz H., Shore R.E., Koenig K.L., Kato I., Arslan A.A., et al. Circulating enterolactone and risk of breast cancer: a prospective study in New York. Br J Cancer 2004, 91:99-105.